Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
about
Observational data: Understanding the real MS world.Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French CenterTwo studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Treatment decisions in multiple sclerosis - insights from real-world observational studies.Natalizumab treatment of multiple sclerosis: new insights.Multiple sclerosis e-registries.Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.A longitudinal real-life comparison study of natalizumab and fingolimod.Therapy of highly active pediatric multiple sclerosis.Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab fingolimod efficacy in multiple sclerosisLong-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
P2860
Q30249781-17521AF9-278B-4072-8AB9-A2D7A1899D75Q33639041-BB2B6F7D-AEED-4ECE-A59F-8FFFB1669450Q33642908-5B3C6AFB-1491-4ECB-97E4-3C74BBE9D058Q36148189-BD0F10A4-FF87-4743-A2DE-EE2FE2D69018Q38606914-6EAA7666-C65A-421E-83AA-21FC7CCC7A4DQ39021942-ECD3EA0D-9DB1-4365-BEAE-65C081A820F6Q39022643-26EC0191-E2D7-4E10-BC3A-75BA86BE6D0DQ39048568-6E981581-4C30-4CD3-8FA9-5E20633AEE64Q39164252-56530134-52F4-4231-A506-2CA63D116A08Q39188128-D4FD96FD-BC1E-4BFC-A6ED-5D279F03FE08Q39675286-1324D1A0-2646-42E2-9B1A-8F35F4A6BA28Q48204088-E40FAF0C-AA6B-4899-B8B9-38C30E1146C7Q48650575-AC1D7B68-CC25-4D29-B21D-0382145DD3F4Q49968003-2F13CC6D-4B19-4BA5-8469-EAC4F35C4FD0Q55559824-E552480C-E3AA-4369-9FE1-84CDCC90E323Q58564004-2839C991-65B0-4287-804C-E28E2C912C89Q58793277-6C7D2258-0A8E-48E3-BDD4-1162C8FD40CC
P2860
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Comparative efficacy of fingol ...... ulticenter observational study
@ast
Comparative efficacy of fingol ...... ulticenter observational study
@en
type
label
Comparative efficacy of fingol ...... ulticenter observational study
@ast
Comparative efficacy of fingol ...... ulticenter observational study
@en
prefLabel
Comparative efficacy of fingol ...... ulticenter observational study
@ast
Comparative efficacy of fingol ...... ulticenter observational study
@en
P2093
P2860
P1433
P1476
Comparative efficacy of fingol ...... ulticenter observational study
@en
P2093
Abdullatif Al Khedr
Alain Créange
Ayman Tourbah
Bertrand Bourre
Bruno Brochet
Bruno Stankoff
CFSEP and OFSEP groups
Caroline Papeix
Chloe Rousseau
Christine Lebrun-Frenay
P2860
P304
P356
10.1212/WNL.0000000000002395
P407
P577
2016-01-29T00:00:00Z